<DOC>
	<DOCNO>NCT00840450</DOCNO>
	<brief_summary>This study design determine whether combination treatment Paclitaxel Gleevec recurrent ovarian cancer patient cancer mullerian origin generate well clinical response Paclitaxel alone .</brief_summary>
	<brief_title>Imatinib Mesylate ( Gleevec ) Paclitaxel Recurrent Patients Ovarian Other Cancers Mullerian Origin</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients least 18 year age . Histologically documented diagnosis epithelial carcinoma arise ovary , fallopian tube peritoneum , stage grade diagnosis . *Patients must receive initial cytoreductive surgery chemotherapy least one platinum base chemotherapy regimen . *Eligible platinum resistant patient fail two additional non platinum cytotoxic regimens persistent recurrent disease . Measurable disease . Performance status 0 , 1 , 2 ( Eastern Cooperative Oncology Group ) . Adequate end organ function , define follow : total bilirubin &lt; 1.5 x upper limit normal ( ULN ) , SGOT SGPT &lt; 2.5 x UNL , creatinine &lt; 1.5 x ULN , ANC &gt; 1.0 x 10E9/L , platelet &gt; 100 x 10E9/L . Written , voluntary inform consent . Patient receive anticancer treatment within 21 day first day study drug dose show recovery recent druginduced neutropenia thrombocytopenia . Patient another primary malignancy require active intervention within 5 year , exception basal cell skin cancer cervical carcinoma situ . Patient Grade III/IV cardiac problem define New York Heart Association Criteria ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . Patients coumadinderived anticoagulant . Patient brain metastasis . Chronic liver disease , Hep B C. Patient know diagnosis human immunodeficiency virus ( HIV ) infection . Patient receive chemotherapy within 3 week unless disease rapidly progress . Patient previously receive radiotherapy least 25 % bone marrow . Patient major surgery within 2 week prior study entry . Patient significant history noncompliance medical regimen inability grant reliable informed consent . Patient drug may interfere Gleevec ( e.g. , Dilantin , Coumadin , others list page 3337 protocol ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>recurrent</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxane</keyword>
	<keyword>mullerian</keyword>
</DOC>